Biotech News

Carisma Announces Delisting from Nasdaq and SEC Deregistration

Carisma Therapeutics, Inc. (CARM)Carisma Therapeutics, Inc.2026-06-25 13:46 ESTSEC filing

PHILADELPHIA , Dec. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends to proceed with the voluntary delisting of its common stock from The Nasdaq Stock Market LLC ("Nasdaq")

Open original release

Related news

CARMCarisma Therapeutics, Inc.2026-06-25 13:46 EST

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

CARMCarisma Therapeutics, Inc.2026-06-25 13:46 EST

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

CARMCarisma Therapeutics, Inc.2026-06-25 13:46 EST

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

CARMCarisma Therapeutics, Inc.2026-06-25 13:46 EST

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024

CARMCarisma Therapeutics, Inc.2026-06-25 13:46 EST

Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

CARMCarisma Therapeutics, Inc.2026-06-25 13:46 EST

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

CARMCarisma Therapeutics, Inc.2026-06-25 13:46 EST

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

CARMCarisma Therapeutics, Inc.2026-06-25 13:46 EST

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

CARMCarisma Therapeutics, Inc.2026-06-25 13:46 EST

Carisma Therapeutics Provides Corporate Updates

XOMAXOMA Corporation2026-07-14 13:00 EST

XOMA Royalty Announces Closing of Its Acquisition by Ligand

View all latest news

Carisma Therapeutics, Inc.

Carisma Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

CARMZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

CARMZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

CARMBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

CARMGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

CARMMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 0.01 USD
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States